InvestSMART

Immuron Limited (ASX:IMC)

ALERT: Price-sensitive ASX Announcement for IMC
Current share price for IMC : $0.037 -0.006 (-13.95%)+
Announcement
Release
16 Jul 2026 10:22AM
Price at Release
$0.043
Full Release
download
Summary
Immuron Limited has announced continued sales growth for FY26, driven by the performance of their product Travelan®. Global sales reached AUD$7.7 million, marking a 6% increase over the previous year. In Australia, sales grew by 10% due to enhanced digital marketing and increased travel in Southeast Asia. U.S. sales also rose by 7% in AUD and 13% in USD, supported by expanded presence on e-commerce platforms and social media marketing. In Canada, the company witnessed significant quarterly growth, although overall sales declined by 55% compared to the previous year. These achievements were partly offset by currency fluctuations. Immuron's efforts in developing oral polyclonal antibodies for infectious diseases continue to show promise, particularly with their Travelan® product which targets travelers' diarrhea.
Key Points
  • FY26 global sales reached AUD$7.7 million, up 6% from the prior year.
  • Australian sales increased by 10% due to effective digital marketing and increased regional travel.
  • U.S. sales grew by 7% in AUD and 13% in USD, supported by online retail enhancements.
  • Canadian market saw a quarterly sales surge despite an annual decline.
  • Currency exchange rates, particularly the AUD to USD, impacted sales figures.
  • Immuron continues to develop and market Travelan®, an immune supplement targeting travelers' diarrhea.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.